Comparison of outcomes between older (≥50 years) and younger (<50 years) patients
| . | Older group (N = 27) . | Younger group (N = 38) . | P . |
|---|---|---|---|
| 1 year GRFS, % | 84 | 94 | .23 |
| 5 year OS, % | 86 | 96 | .14 |
| I year TRM, % | 14 | 5.4 | .23 |
| CI acute GVHD, % | 4 | 5 | .93 |
| CI chronic GVHD, % | 18 | 14 | .65 |
| Median time to neutrophil engraftment (range), d | 12 (9-20) | 11 (9-19) | .9 |
| Median time to platelet engraftment (range), d | 13 (9-61) | 12 (9-61) | .9 |
| Graft failure, n (%) | 1 (3.7), late | 2 (5.3), 1 early, 1 late | 1.0 |
| Median CD3 chimerism (range), % | |||
| Day +100 | 59 (1-100) | 42 (2-100) | |
| 1 y | 64 (23-98) | 71 (35-100) | |
| 3 y | 60 (22-98) | 79 (50-100) | |
| CMV reactivation, n (%) | 9 (33) | 9 (24) | .4 |
| Multiple (>1) CMV reactivation, n | 4 | 2 | .22 |
| CMV disease, n | 1 | 1 | |
| EBV reactivation, n (%) | 10 (37) | 15 (39) | .79 |
| EBV PTLD, n | 0 | 2 | |
| Second cancers, n | 0 | Squamous cell cervical carcinoma (n = 1), hepatocellular carcinoma (n = 1), classical Hodgkin lymphoma (n = 1) | |
| Causes of death | Invasive fungal disease, days +14, +16, +21 (n = 3); MOF with recurrent parainfluenza and CMV infection day +327 (n = 1) | Sepsis, MOF, portal vein thrombosis, day +213 (n = 1); invasive fungal disease, day +16 (n = 1) | Fungal disease .15 |
| . | Older group (N = 27) . | Younger group (N = 38) . | P . |
|---|---|---|---|
| 1 year GRFS, % | 84 | 94 | .23 |
| 5 year OS, % | 86 | 96 | .14 |
| I year TRM, % | 14 | 5.4 | .23 |
| CI acute GVHD, % | 4 | 5 | .93 |
| CI chronic GVHD, % | 18 | 14 | .65 |
| Median time to neutrophil engraftment (range), d | 12 (9-20) | 11 (9-19) | .9 |
| Median time to platelet engraftment (range), d | 13 (9-61) | 12 (9-61) | .9 |
| Graft failure, n (%) | 1 (3.7), late | 2 (5.3), 1 early, 1 late | 1.0 |
| Median CD3 chimerism (range), % | |||
| Day +100 | 59 (1-100) | 42 (2-100) | |
| 1 y | 64 (23-98) | 71 (35-100) | |
| 3 y | 60 (22-98) | 79 (50-100) | |
| CMV reactivation, n (%) | 9 (33) | 9 (24) | .4 |
| Multiple (>1) CMV reactivation, n | 4 | 2 | .22 |
| CMV disease, n | 1 | 1 | |
| EBV reactivation, n (%) | 10 (37) | 15 (39) | .79 |
| EBV PTLD, n | 0 | 2 | |
| Second cancers, n | 0 | Squamous cell cervical carcinoma (n = 1), hepatocellular carcinoma (n = 1), classical Hodgkin lymphoma (n = 1) | |
| Causes of death | Invasive fungal disease, days +14, +16, +21 (n = 3); MOF with recurrent parainfluenza and CMV infection day +327 (n = 1) | Sepsis, MOF, portal vein thrombosis, day +213 (n = 1); invasive fungal disease, day +16 (n = 1) | Fungal disease .15 |
EBV, Ebstein-Barr virus; MOF, multiorgan failure; PRCA, pure red cell aplasia; PTLD, posttransplant lymphoproliferative disorder.